Exelixis Announces June 3 Webcast of Clinical Investigator Discussions of Phase I Trial Results of XL647, XL880 and XL999
Posted on: Thursday, 25 May 2006, 18:00 CDT
SOUTH SAN FRANCISCO, Calif., May 25 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that senior management and clinical investigators will discuss new clinical data on XL647, XL880 and XL999 in conjunction with data presentations held at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) at 6:00 p.m. ET / 3:00 p.m. PT on Saturday, June 3, 2006.
The discussion will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com/.
About Exelixis
Exelixis, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics that will potentially enhance the care and lives of patients with cancer and other serious diseases. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a multinational Phase III clinical trial in bile duct tumor is ongoing and which has been exclusively licensed to Helsinn Healthcare S.A.; XL784, which is being advanced in a Phase II trial as a treatment for renal disease; XL999, an anticancer compound currently in Phase II clinical trials for a variety of solid tumors; XL647, XL880, XL820, XL844 and XL184, anticancer compounds currently in Phase I clinical trials; and multiple compounds in preclinical development for diseases including cancer and various metabolic and cardiovascular disorders. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between Exelixis and GSK, GSK has the option, after completion of clinical proof-of-concept by Exelixis, to elect to develop a certain number of compounds in Exelixis' product pipeline, which may include XL784 and the cancer compounds identified in this press release (other than XL119), thus potentially triggering milestone payments and royalties from GSK and co-promotion rights by Exelixis. For more information, please visit the company's web site at http://www.exelixis.com/.
Exelixis, Inc.
CONTACT: investors, Charles Butler, Director, Corporate Communications,+1-650-837-7277, or cbutler@exelixis.com, or media, Soleil Maxwell Harrison,Manager, Corporate Communications, +1-650-837-7012, or sharrison@exelixis.com,both of Exelixis, Inc.
Web site: http://www.exelixis.com/
Source: PRNewswire-FirstCall
Related Articles
- Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development
- Patents Issued for Inotek Pharmaceuticals' Lead Clinical Compounds in Glaucoma and Contrast-Induced Nephropathy
- Prominent Scientist to Lead Intrexon's Clinical Research and Development
- Exelixis Testing Gastric-Cancer Drug
- Genaera Appoints Anthony DelConte, MD, As Vice President of Clinical Research and Development
- DNAPrint Genomics Selects PT-502 Lead Research Compound for Development of Drug for Treating Depression
- Genaera Appoints Michael J. Gast, MD, PhD to Lead Clinical Research and Development
- Cirrus Health Appoints Barry D. Smith As Vice President of Clinical Service Line Development
- Avera Pharmaceuticals Names Joao Siffert, M.D. As Vice President, Clinical Research and Development
- Efficacy and Safety Clinical Data for Rigel's R112 Phase II Study Published in Journal of Allergy and Clinical Immunology
 |
 |
User Comments (0)
RSS Feeds